Burn and trauma units as sources of methicillin-resistant Staphylococcus aureus

Linda Phillips, J. P. Heggers, M. C. Robson

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

At the time that methicillin-resistant Staphylococcus aureus (MRSA) began to achieve clinical prominence, it was thought to be spread by exogenous vectors. Institution of rigorous infection control efforts, including isolation procedures, was found to have little effect on the frequency of MRSA colonization of burn wounds. It was later found that handwashing was sufficient to prevent cross-contamination. Subsequently, it has been shown that patients can be harboring MRSA at the time of admission to the burn unit and that multiple antimicrobial resistance can develop among organisms that reside in the patient through plasmid-mediated transfer of resistance genes. Excessive use of such agents as the synthetic penicillins and second- and third-generation cephalosporins has selected for the survival of these organisms. Currently, the only available agent for systemic treatment of MRSA infection is vancomycin, the use of which is expensive and associated with significant toxicity. Muciprocin is a topical antimicrobial that promises to be useful in the treatment of such infections. Other agents for systemic use are needed, since use of a single drug to combat MRSA infections seems likely to encourage the emergence of resistant organisms.

Original languageEnglish (US)
Pages (from-to)293-297
Number of pages5
JournalJournal of Burn Care and Rehabilitation
Volume13
Issue number2 II
StatePublished - 1992

Fingerprint

Burn Units
Trauma Centers
Methicillin-Resistant Staphylococcus aureus
Infection
Hand Disinfection
Cephalosporins
Vancomycin
Infection Control
Penicillins
Plasmids
Survival
Wounds and Injuries
Therapeutics
Pharmaceutical Preparations
Genes

ASJC Scopus subject areas

  • Emergency Medicine
  • Rehabilitation
  • Surgery
  • Nursing(all)
  • Health Professions(all)

Cite this

Burn and trauma units as sources of methicillin-resistant Staphylococcus aureus. / Phillips, Linda; Heggers, J. P.; Robson, M. C.

In: Journal of Burn Care and Rehabilitation, Vol. 13, No. 2 II, 1992, p. 293-297.

Research output: Contribution to journalArticle

@article{a7fb2d8c7fea463d83963b88a6eb65cc,
title = "Burn and trauma units as sources of methicillin-resistant Staphylococcus aureus",
abstract = "At the time that methicillin-resistant Staphylococcus aureus (MRSA) began to achieve clinical prominence, it was thought to be spread by exogenous vectors. Institution of rigorous infection control efforts, including isolation procedures, was found to have little effect on the frequency of MRSA colonization of burn wounds. It was later found that handwashing was sufficient to prevent cross-contamination. Subsequently, it has been shown that patients can be harboring MRSA at the time of admission to the burn unit and that multiple antimicrobial resistance can develop among organisms that reside in the patient through plasmid-mediated transfer of resistance genes. Excessive use of such agents as the synthetic penicillins and second- and third-generation cephalosporins has selected for the survival of these organisms. Currently, the only available agent for systemic treatment of MRSA infection is vancomycin, the use of which is expensive and associated with significant toxicity. Muciprocin is a topical antimicrobial that promises to be useful in the treatment of such infections. Other agents for systemic use are needed, since use of a single drug to combat MRSA infections seems likely to encourage the emergence of resistant organisms.",
author = "Linda Phillips and Heggers, {J. P.} and Robson, {M. C.}",
year = "1992",
language = "English (US)",
volume = "13",
pages = "293--297",
journal = "Journal of Burn Care and Research",
issn = "1559-047X",
publisher = "Lippincott Williams and Wilkins",
number = "2 II",

}

TY - JOUR

T1 - Burn and trauma units as sources of methicillin-resistant Staphylococcus aureus

AU - Phillips, Linda

AU - Heggers, J. P.

AU - Robson, M. C.

PY - 1992

Y1 - 1992

N2 - At the time that methicillin-resistant Staphylococcus aureus (MRSA) began to achieve clinical prominence, it was thought to be spread by exogenous vectors. Institution of rigorous infection control efforts, including isolation procedures, was found to have little effect on the frequency of MRSA colonization of burn wounds. It was later found that handwashing was sufficient to prevent cross-contamination. Subsequently, it has been shown that patients can be harboring MRSA at the time of admission to the burn unit and that multiple antimicrobial resistance can develop among organisms that reside in the patient through plasmid-mediated transfer of resistance genes. Excessive use of such agents as the synthetic penicillins and second- and third-generation cephalosporins has selected for the survival of these organisms. Currently, the only available agent for systemic treatment of MRSA infection is vancomycin, the use of which is expensive and associated with significant toxicity. Muciprocin is a topical antimicrobial that promises to be useful in the treatment of such infections. Other agents for systemic use are needed, since use of a single drug to combat MRSA infections seems likely to encourage the emergence of resistant organisms.

AB - At the time that methicillin-resistant Staphylococcus aureus (MRSA) began to achieve clinical prominence, it was thought to be spread by exogenous vectors. Institution of rigorous infection control efforts, including isolation procedures, was found to have little effect on the frequency of MRSA colonization of burn wounds. It was later found that handwashing was sufficient to prevent cross-contamination. Subsequently, it has been shown that patients can be harboring MRSA at the time of admission to the burn unit and that multiple antimicrobial resistance can develop among organisms that reside in the patient through plasmid-mediated transfer of resistance genes. Excessive use of such agents as the synthetic penicillins and second- and third-generation cephalosporins has selected for the survival of these organisms. Currently, the only available agent for systemic treatment of MRSA infection is vancomycin, the use of which is expensive and associated with significant toxicity. Muciprocin is a topical antimicrobial that promises to be useful in the treatment of such infections. Other agents for systemic use are needed, since use of a single drug to combat MRSA infections seems likely to encourage the emergence of resistant organisms.

UR - http://www.scopus.com/inward/record.url?scp=0026663970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026663970&partnerID=8YFLogxK

M3 - Article

C2 - 1577842

AN - SCOPUS:0026663970

VL - 13

SP - 293

EP - 297

JO - Journal of Burn Care and Research

JF - Journal of Burn Care and Research

SN - 1559-047X

IS - 2 II

ER -